Announced details
Nerve regeneration, and functional recovery and improved quality of life for stroke and spinal cord injury patients
Under the partnership, ステムセル研究所 will undertake the manufacture of umbilical cord-derived stem cell culture supernatant based on instructions from physicians at ニューロテックメディカル’s affiliated clinics. ニューロテックメディカル will consider using “Family Culture Supernatant®” at its affiliated clinics.
Head office: Murakami Jitsugyo Building 216, 1-13-13 Chuo, Joto-ku, Osaka, Osaka; Representative Director and President: Kihōin Eitoshi (貴宝院永稔); established: 27 December 2019; capital: ¥349.844 million. A medical technology company focused on functional recovery and improving quality of life for stroke and spinal cord injury patients.
ステムセル研究所: 2nd Floor, Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo. ニューロテックメディカル: Murakami Jitsugyo Building 216, 1-13-13 Chuo, Joto-ku, Osaka, Osaka.
The impact on ステムセル研究所’s results is immaterial.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Family Culture Supernatant®, ReNeuro®, Targeted Nerve Regenerative Medicine™, Targeted Rehabilitation™ |
| Counterparty | ニューロテックメディカル株式会社 |
| Counterparty overview | Head office: Murakami Jitsugyo Building 216, 1-13-13 Chuo, Joto-ku, Osaka, Osaka; Representative Director and President: Kihōin Eitoshi (貴宝院永稔); established: 27 December 2019; capital: ¥349.844 million. A medical technology company focused on functional recovery and improving quality of life for stroke and spinal cord injury patients. |
| Relationship with the Company | Under the partnership, ステムセル研究所 will undertake the manufacture of umbilical cord-derived stem cell culture supernatant based on instructions from physicians at ニューロテックメディカル’s affiliated clinics. ニューロテックメディカル will consider using “Family Culture Supernatant®” at its affiliated clinics. |
| Launch date | Partnership begins on 3 July 2026 (stated as the start date, not as a planned date) |
| Applicable area | Nerve regeneration, and functional recovery and improved quality of life for stroke and spinal cord injury patients |
| Location | ステムセル研究所: 2nd Floor, Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo. ニューロテックメディカル: Murakami Jitsugyo Building 216, 1-13-13 Chuo, Joto-ku, Osaka, Osaka. |
| Impact on Business Performance | The impact on ステムセル研究所’s results is immaterial. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To leverage the two companies’ respective expertise and establish a system for delivering new medical services.